home / stock / msclf / msclf quote
Last: | $0.3956 |
---|---|
Change Percent: | 5.56% |
Open: | $0.38493 |
Close: | $0.3956 |
High: | $0.41 |
Low: | $0.38493 |
Volume: | 7,000 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.3956 | $0.38493 | $0.3956 | $0.41 | $0.38493 | 7,000 | 07-02-2024 |
$0.4076 | $0.4342 | $0.4076 | $0.4342 | $0.4076 | 1,600 | 07-01-2024 |
$0.4431 | $0.4331 | $0.4431 | $0.4431 | $0.40155 | 7,650 | 06-28-2024 |
$0.40655 | $0.4431 | $0.40655 | $0.4431 | $0.3877 | 1,791 | 06-27-2024 |
$0.3877 | $0.3877 | $0.3877 | $0.3891 | $0.3877 | 22,515 | 06-26-2024 |
$0.44874 | $0 | $0.44874 | $0 | $0 | 300,000 | 06-25-2024 |
$0.44874 | $0.4329 | $0.44874 | $0.44874 | $0.4329 | 2,200 | 06-24-2024 |
$0.47 | $0.4721 | $0.47 | $0.578 | $0.44135 | 114,245 | 06-21-2024 |
$0.3885 | $0.3853 | $0.38845 | $0.3885 | $0.3853 | 3,050 | 06-19-2024 |
$0.38845 | $0.3853 | $0.38845 | $0.38845 | $0.3853 | 3,050 | 06-18-2024 |
$0.393 | $0.393 | $0.393 | $0.393 | $0.393 | 8,000 | 06-17-2024 |
$0.4139 | $0 | $0.4139 | $0 | $0 | 500 | 06-14-2024 |
$0.4139 | $0.42285 | $0.4139 | $0.4229 | $0.4139 | 10,281 | 06-12-2024 |
$0.3321 | $0.3321 | $0.3321 | $0.3321 | $0.3321 | 625 | 06-11-2024 |
$0.3776 | $0 | $0.3776 | $0 | $0 | 5 | 06-06-2024 |
$0.3776 | $0.3776 | $0.3776 | $0.37785 | $0.3776 | 15,000 | 05-31-2024 |
$0.3833 | $0.38 | $0.3833 | $0.3833 | $0.38 | 56,400 | 05-30-2024 |
$0.3546 | $0.364 | $0.3546 | $0.364 | $0.3546 | 3,467 | 05-29-2024 |
$0.36 | $0.3568 | $0.36 | $0.36 | $0.3568 | 4,850 | 05-28-2024 |
$0.3251 | $0.3474 | $0.3251 | $0.35 | $0.32 | 27,950 | 05-23-2024 |
News, Short Squeeze, Breakout and More Instantly...
–SAT-3247 treatment improved muscle repair and regeneration in canine model of DMD – SAT-3247 treatment also improved muscle force in this canine model of DMD – Satellos remains on track to initiate a Phase 1 clinical trial in Q3 2024 Satellos Bios...
– Frank Gleeson, Satellos CEO, to participate in a panel discussion titled "Research Row: PPMD Moving the Needle" on June 29, 2024 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company d...
Satellos expects to begin first-in-human clinical trials mid-year for SAT-3247, an oral small molecule drug candidate in development as a novel regenerative medicine approach to treating DMD Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSC...